Drug recall · August 30, 2023
Trandolapril and Verapamil Hydrochloride Extended-Release Tablets 2 mg / 180 mg recall
Why: Subpotent: Out of Specification for Assay Test at the 3-month time point.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Trandolapril and Verapamil Hydrochloride Extended-Release Tablets 2 mg / 180 mg, 100-count Bottle, Rx only, Manufactured by: Glenmark Pharmaceuticals Ltd. Colvale -Bardez, Goa 403513, India, Manufactured for Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, NDC 68462-295-01
- Lots / codes
Batch # 19224744
- Quantity
- 1,200 bottles
- Company
- Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ
- Distribution
- nationwide in the U.S.
- Initiated
- August 14, 2023 · Voluntary: Firm initiated
- Classified
- August 22, 2023
- Reported
- August 30, 2023
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Verapamil
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.